Although ␤ blockers have had significant impact in the treatment of portal hypertension, the question of how long they should be continued for prevention of variceal hemorrhage remains unknown. Prospective studies on ␤ blockers to prevent variceal hemorrhage lack long-term follow-up, and indefinite administration of ␤ blockers for primary prevention of variceal bleeding has become standard practice. The aim of this study was to determine the outcomes of patients in whom ␤ blocker therapy was discontinued. Patients completing a prospective, randomized, double-blind, placebo-controlled trial of propranolol for the primary prevention of variceal hemorrhage were tapered off of propranolol and placebo and followed prospectively for subsequent events. Of the 49 patients in the follow-up study (25 former propranolol, 24 former placebo), 9 experienced variceal hemorrhage (6 former propranolol, 3 former placebo). Following withdrawal of propranolol, the freedom from variceal bleeding was not significantly different between these 2 groups of patients, suggesting that the protective effect of propranolol against variceal hemorrhage, noted previously, was no longer present. Seventeen patients died (12 former propranolol, 5 former placebo) during the follow-up study. Cumulative survival was longer in the placebo group. These trends for EVH and survival were opposite to those observed in the original study population while patients were taking medication. When propranolol is withdrawn, the risk of variceal hemorrhage returns to what would be expected in an untreated population. Patients who discontinue ␤ blockers experience increased mortality compared with an untreated population. These observations support the current practice of indefinite prophylactic therapy. (HEPATOLOGY 2001;34:1096-1102.) 
Multiple clinical trials have shown nonselective ␤ blockers to be effective in the prevention of first variceal hemorrhage. [1] [2] [3] [4] [5] [6] [7] [8] A meta-analysis combining data from these trials showed significant reduction in the risk of first variceal hemorrhage from 25% in controls to 15% in patients treated with ␤ blockers after a median follow-up of 24 months. Although ␤ blockers have had a significant impact in the treatment of portal hypertension, the question of how long they should be continued for prevention of variceal hemorrhage remains unknown. There has been consensus that efficacy of ␤ blockers is limited to their administration, and that they should therefore be continued indefinitely. 10 However, this has never been proven.
That indefinite treatment with ␤ blockers may be unnecessary is suggested by several studies which show that the risk of variceal hemorrhage is highest in the first year after diagnosis of varices and decreases thereafter. In a prospective study of 321 patients with cirrhosis, esophageal varices and no prior variceal bleeding, 85 patients (26.5%) bled from varices during a median follow-up of 23 months. 11 In addition to identifying clinical and endoscopic risk factors for first variceal hemorrhage: advanced Child's Class, size of varices, and the presence of red wale markings, these investigators observed that of the 85 patients who bled, 67% did so within the first year, and 91% within 2 years of the diagnosis of varices. By comparison, a prospective study in patients with primary biliary cirrhosis, 48% of patients bled from varices over a median follow-up of 5.6 years, with 76% of those of patients experiencing their first bleed within 1 year of diagnosis. 12 Older studies on the natural history of variceal hemorrhage, primarily in alcoholic cirrhotic patients, also suggest that the majority of variceal bleeding episodes occurred within the first year of diagnosis of varices. [13] [14] [15] The majority of clinical studies showing the efficacy of ␤ blockers for prevention of variceal hemorrhage report a follow-up period of up to 2 years, as this was considered the period of highest risk. Because of these observations, including the lack of long-term follow up in prospective studies and lack of cost-effectiveness data for indefinite treatment, it may be proposed that ␤ blockers are necessary only during a certain high risk period. After this period, the medication could be tapered off, leaving the patient with a bleeding risk that may be low enough, similar to placebo, to justify observation without medication. However, no study has been designed specifically to address this question, and with the use of ␤ blockers now accepted as standard of care, it is unlikely that such a trial would be ethically justifiable at this time.
A prospective, randomized, double-blind, placebo-controlled trial conducted by the Boston-New Haven-Barcelona Portal Hypertension Study Group (carried out from 1982-1986) on 102 patients with cirrhosis and portal hypertension showed that propranolol effectively prevents first hemorrhage from esophagogastric varices and portal hypertensive gastropathy. 6 At the conclusion of the study, those patients who remained free of esophageal variceal hemorrhage (EVH) and death were tapered off of medication/placebo, respectively, and a subgroup of these patients were followed prospectively for subsequent events. The objective of this follow-up study was to define the course of these patients after withdrawal of propranolol.
PATIENTS AND METHODS

Study Design
Retrospective analysis of a prospective cohort study.
Original Study
One hundred two patients with a clinical diagnosis of cirrhosis and endoscopically documented esophageal varices, who had not previously bled from esophageal varices, participated in an original study of ␤ blocker versus placebo in the prevention of variceal hemorrhage. Patients with a hepatic venous pressure gradient (HVPG) of greater than or equal to 12 mm Hg had their pressure response to propranolol titrated using a previously described technique. 16 This titration determined the amount of propranolol or placebo to be administered during the study to decrease HVPG. Patients were then randomly assigned to 2 groups, independent of their response to the hemodynamic titration with propranolol: 51 were given propranolol and 51 placebo at doses previously determined by HVPG titration. The patients were observed until the last patient randomized had been on therapy for at least 6 months.
Endpoints
EVH. Upper gastrointestinal hemorrhage was defined as hematemesis or melena that reduced the hematocrit by at least 6% or required blood transfusions. The diagnosis of hemorrhage from varices was based on the endoscopic visualization of an actively bleeding varix, a fresh clot or eschar on the surface of a varix or the presence of esophageal varices in the absence of any other possible bleeding site in the upper gastrointestinal tract. Freedom from EVH is expressed in days after randomization.
Death. Survival is expressed in days after randomization. The mean period of observation in the original study was 16.3 months Ϯ12 months for the placebo group and 17.1 Ϯ 10.9 months for the propranolol group. The protocol was approved by the human investigation committees at each of the participating hospitals. All patients gave informed, written consent to participate in the investigation.
Follow-up Study
Inclusion criteria for the follow-up study were: (1) patients participating in the original study who did not reach study endpoints of death, EVH, or side effects, and (2) patients who had been compliant with medication for at least 6 months during the original study. Of the 102 original study patients, 26 met endpoints of EVH or death, and 12 were withdrawn from the study because of side effects. Of the remaining 64 patients, 15 were excluded from the follow-up study for the following reasons: took medication Ͻ6 months (3 propranolol, 4 placebo), lost to follow-up (4 propranolol), comorbid conditions greatly affecting the ability of the patient to participate (3 propranolol, 1 placebo). Thus, 49 patients (24 placebo, 25 propranolol) were followed prospectively, and these included the 42 patients in whom medication/placebo was tapered at the end of the original study (20 propranolol, 22 placebo) , and 7 dropout patients from the original study (2 placebo: dropped out after 376 and 712 medication days, respectively; 5 propranolol: dropped out after 323, 483, 483, 638, and 1,121 medication days) who were compliant (Ͼ75% pill count) for at least 6 months.
Patients participating in the follow-up study underwent clinical evaluation by reassessment of Child's Score, presence of ascites or encephalopathy, nutrition index, and measurements of serum albumin and bilirubin concentrations. No routine HVPG measurements or endoscopies were done.
Endpoints
EVH as defined earlier. Cumulative freedom from EVH is expressed in days after discontinuation of medication/placebo. Survival is also expressed in days after discontinuation of medication/placebo.
Statistical Analysis
Statistical analyses were performed on an intention-to-treat strategy. Quantitative variables are presented as means Ϯ SD, and Student's t test was used to compare differences. 2 
and Fisher's Exact
Test were used to compare categorical variables. Kaplan-Meier method was used to calculate probabilities of survival and freedom from EVH, and differences were compared by log rank test. Cox Proportional Hazard Analysis was used for the adjusted analyses in the follow-up study. The SPSS 9.0 statistical software package (SPSS Inc., Chicago, IL) was utilized. Two-sided P values of Յ .05 were considered to be statistically significant.
RESULTS
Forty-nine patients met criteria for inclusion (25 former propranolol, 24 former placebo) in the follow-up study. The 2 groups were similar in demographic characteristics of age, sex, type of liver disease, HVPG, variceal size, presence of ascites, PSE, nutrition status, and albumin and bilirubin concentrations measured at the time of discontinuation of medication ( Table 1 ). The 2 groups were also similar in duration of medication received in the original study (which is effectively the same as the time from diagnosis of varices to the beginning of the follow-up study), time from randomization to date last seen, and time from discontinuation of medication to event/ date last seen (Tables 1 and 2 ). Statistically significant differences in baseline characteristics between the 2 groups at the beginning of the follow-up study (coinciding with the time at which medication was discontinued) were use of alcohol during the original study, pill compliance in the original study, and Child's Score at the time of discontinuation of medication. These variables were adjusted for in the analyses of survival and freedom from EVH. Data on alcohol consumption was not collected during the follow-up study; therefore, the impact of alcohol use on our results was taken into account from data from the original study.
EVH
In the original study, 2/51 (4%) patients in the propranolol group bled from esophageal varices (EV) compared with 11/51 (22%) of patients in the placebo group. This difference is statistically significant (P ϭ .0065, log rank) (Fig. 1) .
In the follow-up study, 6/25 (24%) patients in the former propranolol group bled from EV compared with 3/24 (12.5%) in the former placebo group (P ϭ .229) ( Table 2 ). The difference in cumulative freedom from EVH between these 2 groups is not statistically significant (P ϭ .8296) (Fig. 2) . There is no significant difference between the 2 groups in the mean time to EVH after discontinuation of medication; the time from discontinuation of propranolol to EVH was long enough to exclude the possibility of a rebound effect from propranolol discontinuation ( Table 2 ). The earliest bleeding episode in the former propranolol group was 33 days after discontinuation of medication; the earliest bleeding episode in the former placebo group was at 64 days after discontinuation of placebo; there were no bleeding episodes among the 7 dropout patients. Of the 6 patients in the former propranolol group with EVH, 3 had small varices, and 3 had moderatelarge size varices at the beginning of the follow-up study; of the 3 patients in the former placebo group with EVH, 1 had small varices, and 2 had moderate-large size varices (Table 2) .
Survival
In the original study, 8/51 (16%) patients died in the propranolol group compared with 11/51 (22%) in the placebo group. Cumulative survival was longer in the propranolol group, but the difference is not statistically significant (P ϭ .3177, log rank) (Fig. 3) .
In the follow-up study, 12/25 (48%) patients in the former propranolol group died compared with 5/24 (20.8%) in the former placebo group. (P ϭ .046) ( Table 2 ). In contrast to the original study, the follow-up study shows that cumulative survival was longer in the placebo group; the relative risk of death for the former propranolol group was 2.80, but this difference is not statistically significant (P ϭ .2967) (Fig. 4) . There is no significant difference between the 2 groups in the mean time to death after discontinuation of medication ( Table 2) .
The causes of death in the follow-up study were multiple in both groups. The frequencies of death from hepatic failure with or without hepatorenal syndrome, and nonhepatic causes were similar in both groups. Death from EVH occurred in 4 patients in the former propranolol group and none in the placebo group, which is a notable trend, but one which cannot be analyzed statistically because of lack of events in the placebo group (Table 3) .
DISCUSSION
Though multiple clinical trials have shown nonselective ␤ blockers to be effective in the prevention of first variceal hemorrhage, 1-8 the durability of their effects and the value of their continued administration over longer periods of time have not been evaluated. Previous observational studies on the natural history of variceal bleeding have shown that 25% to 40% of patients with documented varices will experience variceal hemorrhage, with the majority of patients experiencing their first bleed within 1 year of diagnosis. 7 The mean follow-up period for clinical trials evaluating ␤ blockers in the prevention of variceal hemorrhage has been about 2 years. The longest published follow-up of patients on propranolol for prevention of variceal bleeding was a median of 55 months. However, this study did not have a control group, and no attempt was made to identify the site of upper gastrointestinal bleeding. 18 Therefore, despite its lengthy follow-up, this study did not directly show that long-term propranolol administration continues to prevent variceal bleeding compared with a control group. Alhough it is clear that ␤ blockers prevent variceal bleeding during the high risk period relative to the endoscopic diagnosis of varices, it is unclear if they should be continued indefinitely, and whether they continue to prevent or simply postpone variceal bleeding in patients in whom they are withdrawn.
A prospective, randomized, double-blind, placebo-controlled trial showed that propranolol effectively prevented first hemorrhage from esophagogastric varices and portal hypertensive gastropathy, 6 but had no statistically significant impact on mortality. At the conclusion of the study, patients who remained free of EVH/death were tapered off of medication/placebo respectively, and a subgroup of these patients were followed prospectively for further events. Preliminary data suggested that the risk of variceal hemorrhage recurred after ␤ blocker withdrawal. 19 Ultimately, forty-nine patients were followed prospectively for further events, in what we refer to as the follow-up study.
Our analysis shows that at the beginning of the follow-up study, which coincided with the time of discontinuation of medication/placebo, the former propranolol group and former placebo groups were comparable in most, but not all of their characteristics. Statistically significant differences were observed in the Child's Score, use of alcohol during the original study, and pill compliance in the original study (Table 1) . These differences (not present at the time of randomization for the original study) suggest that the group tapered off of propranolol was sicker, more compliant with medications in the original study, and consumed more alcohol during the original study compared with the group tapered off of placebo. Explanations for these differences include the possibility that the placebo group experienced more death and EVH during the original study, and, having met these endpoints, could not qualify for the follow-up study, i.e., selection bias. Alternatively, it is possible that, compared with the placebo group, the patients on propranolol experienced some deterioration in their liver function due to, for example, the effect of ␤ blockers decreasing portal blood flow. However, in the original study, there was no increase in the number of deaths related to liver failure between the 2 groups. The differences between the groups, specified earlier, were adjusted for in the follow-up study analyses of survival and freedom from EVH. The adjusted Cox Proportional Hazard analysis (Fig. 2 ) shows a merging of the curves for freedom from EVH, suggesting that the risk of bleeding in patients withdrawn from ␤ blockers recurs, and is similar to that of patients on no medication at a similar stage in time relative to the diagnosis of varices. In the context of what is known about rates of EVH over time, one interpretation of this result is that propranolol protects patients through the initial, highest risk period for variceal bleeding, i.e., the first 2 years after diagnosis, and, that after discontinuation of propranolol, the risk of EVH returns to a level less than that at the time of diagnosis of varices. Whether this lower bleeding risk could justify discontinuation of medication is unknown. Alternatively, these observations could reflect a Type II error: a potential difference in EVH rates after discontinuation of propranolol cannot be detected given the small numbers of patients in the follow-up study.
To further address whether propranolol prevents or merely postpones variceal bleeding, incremental rates of EVH among patients with EVH in the Boston-New Haven-Barcelona Portal Hypertension study placebo group and those sequentially on and off propranolol, were compared with incremental EVH rates as a function of time among patients from older prospective and retrospective trials on the natural history of variceal bleeding. These older studies suggested that, in patients with alcoholic and nonalcoholic causes of cirrhosis, the risk of variceal hemorrhage is highest in the first year after diagnosis of varices, and decreases with time afterward. [11] [12] [13] [14] [15] 20 (Fig. 5 ). These observations may reflect the true natural history of portal hypertension and variceal bleeding or, alternatively, may represent an artifact of selection criteria for clinical studies. 21 The rates of EVH events from the placebo group of the original study and from this same group off placebo in the follow-up study mirror the natural history rates of EVH previously published in the literature (Figs. 5 and 6 ). Given the variable methods and populations of patients, differences in EVH rates cannot be compared statistically between the various trials. However, there appear to be consistent trends among the placebo and natural history patients of the various trials. In contrast, the rate of EVH events from the propranolol group of the original study are markedly decreased, reflecting the protective effect of propranolol during the first and second years of the study. Between the second and third year, and thereafter, the increased rate of EVH reflects events in patients in the former propranolol group in the follow-up study. This suggests that not only does the rate of EVH increase after discontinuation of propranolol, but this rate surpasses the background EVH rate in a group of patients followed prospectively for a similar period of time since the diagnosis of varices. This implies that propranolol may in fact only postpone variceal bleeding, and that patients discontinued from propranolol return to a state of relative increased risk, which would definitely justify continued administration of propranolol.
In contrast to the trends noted in the original study (Fig. 3) , in which cumulative survival was better in the propranolol group, the survival analysis (Fig. 4) for the follow-up study shows improved cumulative survival in the former placebo group; though the difference is not statistically significant, the relative risk of death of 2.8 in the former propranolol group suggests that patients who discontinue ␤ blockers have higher mortality than placebo patients at similar points in time relative to the diagnosis of varices. Although the 2 analysis (Table 2) does not take into account the passage of time, it does show significantly higher mortality in the former propranolol group. The higher mortality rate in the former propranolol group does not correlate with any particular cause of death, however there were 4/12 deaths resulting from EVH in the former propranolol group and 0/5 deaths resulting from EVH in the placebo group, which may contribute to the mortality differences observed. That this subgroup contributes to increased mortality in the former propranolol group is consistent with conclusions from a combined analysis of 589 patients, which showd a statistically significant reduction in EVH-related mortality resulting from ␤ blockers. 22 Increased mortality in the former propranolol group, if it is related to propranolol withdrawal, indirectly strengthens the argument that propranolol administration improves mortality compared with placebo in patients with gastroesophageal varices, a conclusion that few studies have been able to determine prospectively, likely secondary to type II error.
The calculated risk of bleeding from varices is dependent on clinical and endoscopic factors as well as passage of time since the diagnosis of varices. The endoscopic diagnosis of varices is an arbitrary point in time relative to the true time of variceal formation and growth, so an explanation for why, in the natural history of portal hypertension, patients are more apt to bleed within the first year of diagnosis may have to do with the possibility that there are divergent populations in the natural history of portal hypertension, i.e., those patients whose variceal growth rate and progression of liver disease render them destined to bleed, and those in whom these variables render them destined not to bleed. The clinical and endoscopic predictors of variceal hemorrhage, such as Child's Class, variceal size, and presence of red signs, perhaps reflect these predestined states. Without a group of patients continu- ing on propranolol with which to compare, it is possible that any differences observed between the former placebo and former propranolol patients in the follow-up study are not attributable to propranolol withdrawal, but to some other factor(s), e.g., the natural behavior of divergent populations in the natural history of portal hypertension. However, because the original study was randomized, and the follow-up study analysis was adjusted for variables which became heterogenous over time between the 2 groups, it is unlikely that other factors could be affecting the trends we observed. We believe that the data supports the concept that discontinuation of treatment is associated with a persistent risk of EVH in this patient population, that is predominantly Child's Class A and B, with good liver function, good nutritional status, and a low incidence of ascites or encephalopathy. However, we cannot exclude the possibility that the natural history of variceal hemorrhage may have influenced the findings. Although this study was not initially designed to answer definitively the question of how long ␤ blockers should be continued, the results of the follow-up study suggest that, although propranolol is effective in preventing first variceal hemorrhage, the risk persists with cessation of therapy. However, the precise risk that would, a priori, justify discontinuation of prophylactic therapy is unknown. This data, combined with the observation of relative increased mortality in the former propranolol group suggests a potential survival benefit from indefinite prophylactic therapy. Such a survival benefit, however, may or may not relate to primary prevention of variceal bleeding. Future studies on the value of ␤ blockers for long-term treatment of portal hypertension should evaluate not only clinical efficacy but cost-effectiveness.
